The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
News|Articles|February 13, 2019
Aemcolo for Noninvasive Escheria coli Infection
Author(s)Drew Boxler
Advertisement
Aemcolo (rifamycin, Cosmo Pharmaceuticals)
Indications: treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults.
Dosage: Two 388mg tablets taken orally, twice daily for three days.
Contraindications: known hypersensitivity to rifamycin, any of the other rifamycin class antimicrobial agents (e.g. rifaximin), or any of the components in AEMCOLO
Advertisement
Related to this article
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
3
Expert Discusses Flu and COVID-19 Vaccine Guidance
4
Nicotine Pouches Create Opportunity for Pharmacist Counseling
5